Drug Repurposing: Hospitals and Universities Reducing Trial Costs by 90%

Academic and Clinical Drug Repurposing Reduces Costs by 90%

Hospitals and universities are successfully repurposing existing generic drugs through late-stage clinical trials at costs up to 90% lower than those incurred by the pharmaceutical industry. This parallel research system operates outside the traditional patent system, providing a mechanism to discover affordable treatments for a fraction of the typical R&D expenditure.

According to research led by King’s College London and published in the Cambridge Law Journal, these institutions can conduct substantial numbers of late-stage trials with significantly fewer resources. This cost reduction is possible because the barriers to innovation—expertise, risk, and capital—are substantially lower when working with generic drugs compared to developing new molecular entities.

Why Repurposing Costs are Lower in Academic Settings

The reduced cost of repurposing generic drugs in university and hospital settings is driven by three primary factors:

  • Lower Expertise Requirements: Because the drugs are already manufactured and well-studied, investigators can select projects based on their specific clinical expertise rather than needing to build a drug-development infrastructure from scratch.
  • Reduced Financial Risk: Unlike pharmaceutical companies, the financial viability of a university or hospital does not depend on the eventual authorization and sale of the drug, removing the high-stakes financial pressure associated with new drug launches.
  • Existing Infrastructure: Trials are often approved by existing grant and ethics bodies, utilizing academic and clinical frameworks rather than corporate R&D pipelines.

The Lifecycle of Drug Repurposing

Drug repurposing—finding new therapeutic uses for already authorized drugs—follows a distinct lifecycle based on patent status:

  1. Early Lifecycle (Patented): Pharmaceutical companies actively pursue repurposing to expand the market for their patented drugs. Data indicates companies obtain an average of 32 new regulatory authorizations annually for existing drugs.
  2. Late Lifecycle (Generic): Once a drug becomes generic, pharmaceutical companies typically lose interest in repurposing due to increased competition and lower profit margins. This is where the "hidden" academic system flourishes, using inexpensive generic versions of the drugs for research.

Real-World Applications and Impact

This alternative research system has already produced significant medical outcomes, including:

  • Using cancer drugs to treat leading causes of blindness.
  • Repurposing breast cancer treatments to serve as preventative measures.
  • Utilizing old anti-inflammatory drugs to treat Covid-19.

Dr. Johnathon Liddicoat, Reader in Law at King’s College London, notes that this system offers "enormous potential to help patients at a fraction of the cost," and that governments are beginning to implement programs to formally recognize this research.

Critical Challenges and Industry Counterpoints

While the cost advantages are clear, synthesis of clinical and legal perspectives reveals several systemic hurdles to the widespread adoption of repurposed generics:

Regulatory and Legal Barriers Some practitioners note that there is often no clear regulatory pathway to officially extend the use of a drug for new indications without the manufacturer's consent or the institution becoming a manufacturer itself. This can result in beneficial treatments remaining "off-label" rather than becoming officially approved usages.

Safety and Compounding Risks The transition from a drug's original purpose to a repurposed use can introduce safety risks. For example, in ophthalmology, using Bevacizumab (Avastin) for macular degeneration is significantly cheaper than the approved Lucentis. However, some clinicians avoid this because Avastin must be repackaged by compounding pharmacies for ocular injection, which introduces a risk of contamination and endophthalmitis.

Incentive Misalignment There are concerns regarding the "evergreening" of patents, where companies modify a drug slightly to secure a new patent and maintain high prices. One example cited is the use of esketamine (Spravato) over the cheaper, off-patent ketamine, where the modified version may be less effective but is preferred by insurance companies because it is FDA-approved.

The Need for New Molecules Despite the success of repurposing, some argue that it cannot replace primary drug development. For conditions like long-covid and ME-CFS, where repurposing efforts have not yet yielded cures, the development of entirely new molecules remains critical.

Sources